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Summary
Toxoplasma gondii infections cause a large disease burden in the Netherlands, with an 
estimated health loss of 1,900 Disability Adjusted Life Years and a cost- of- illness esti-
mated at €44 million annually. Infections in humans occur via exposure to oocysts in 
the environment and after eating undercooked meat containing tissue cysts, leading to 
asymptomatic or mild symptoms, but potentially leading to the development of ocular 
toxoplasmosis. Infection in pregnant women can lead to stillbirth and disorders in 
newborns. At present, prevention is only targeted at pregnant women. Cat vaccina-
tion, freezing of meat destined for undercooked consumption and enhancing biosecu-
rity in pig husbandries are possible interventions to prevent toxoplasmosis. As these 
interventions bear costs for sectors in society that differ from those profiting from the 
benefits, we perform a social cost- benefit analysis (SCBA). In an SCBA, costs and ben-
efits of societal domains affected by the interventions are identified, making explicit 
which stakeholder pays and who benefits. Using an epidemiological model, we con-
sider transmission of T. gondii after vaccination of all owned cats or cats at livestock 
farms. To identify relevant high- risk meat products that will be eaten undercooked, a 
quantitative microbial risk assessment model developed to attribute predicted T. gon-
dii infections to specific meat products will be used. In addition, we evaluate serologi-
cal monitoring of pigs at slaughter followed by an audit and tailor made advice for 
farmers in case positive results were found. The benefits will be modelled stochasti-
cally as reduction in DALYs and monetized in Euro’s following reference prices for 
DALYs. If the balance of total costs and benefits is positive, this will lend support to 
implementation of these preventive interventions at the societal level. Ultimately, 
the SCBA will provide guidance to policy makers on the most optimal intervention 
measures to reduce the disease burden of T. gondii in the Netherlands.
K E Y W O R D S
cat vaccination, freezing meat, prevention, risk assessment, social cost-benefit analysis, 
toxoplasmosis
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1  | INTRODUCTION
Toxoplasmosis is caused by the protozoan parasite Toxoplasma 
gondii. This parasite can infect a wide range of warm- blooded ani-
mals such as birds, mice, rats, cats, sheep, pigs and cattle, as well 
as humans. Most species function as intermediate hosts, and they 
will not shed T. gondii in the environment, but infection will lead to 
the development of infectious tissue cysts. Cats and other felids 
function as definitive hosts, meaning that T. gondii can complete its 
sexual cycle resulting in shedding of millions of oocysts in their fae-
ces for up to three weeks (Dabritz & Conrad, 2010). These oocysts 
can remain viable in the environment for about a year (Dumetre 
& Darde, 2003; Frenkel, Ruiz, & Chinchilla, 1975), where they can 
infect other animals, both farm and non- farm animals as well as hu-
mans. Infections in humans occur mostly via exposure to oocysts in 
the environment or after eating raw or undercooked meat contain-
ing tissue cysts, often leading to an asymptomatic infection or mild 
flu- like symptoms (Elmore et al., 2010), but potentially leading to 
the development of ocular toxoplasmosis (Weiss & Dubey, 2009). 
Besides, toxoplasmosis is also well- known as a cause of congenital 
disease in humans. Infection in naïve pregnant women can lead to 
abortion, stillbirth and serious disorders in newborns such as hy-
drocephalus, microcephalus and chorioretinitis later in life (Weiss 
& Dubey, 2009).
As a consequence of these serious health risks, T. gondii is an 
important pathogen in terms of burden of disease in humans in the 
Netherlands. The burden of toxoplasmosis can be distinguished into 
the number of years of life lost (premature mortality) and the number 
of years lived in less than full health (morbidity). The aggregate of both 
measures is a quantification of the years of healthy life lost due to a 
certain disease or infection, better known as the Disability Adjusted 
Life Years (DALYs). It is recently estimated that toxoplasmosis is re-
sponsible for a disease burden (undiscounted) of about 1,903 DALYs 
per year (Mangen, Friesema, Haagsma, & Van Pelt, 2017). With this dis-
ease burden, T. gondii ranks third among all foodborne- related patho-
gens, after Campylobacter spp. that is associated with 3,573 DALYs and 
norovirus with 2,248 DALYs in the Netherlands (Mangen et al., 2017). 
In 2016, the estimated mean annual number of infections of toxoplas-
mosis in the Netherlands was 767, of which 344 were congenital and 
423 were acquired in later life (Mangen et al., 2017). In the same year, 
the estimated mean annual number of deaths was 12. About half of 
all toxoplasmosis- related DALYs are associated with congenital toxo-
plasmosis. Mangen et al. (2017) assessed the cost- of- illness of toxo-
plasmosis in 2016 at € 44 million, considering disease- related costs 
from a societal perspective, which means that in addition to health 
care costs, also productivity losses due to work absence of caregivers 
and patients and the cost of special education were included. In order 
to reduce the burden of disease and associated costs, additional strat-
egies to prevent both congenital and acquired toxoplasmosis in the 
population should be considered.
In the Netherlands, toxoplasmosis prevention currently is only 
targeted at educating and counselling pregnant women (Opsteegh, 
Kortbeek, Havelaar, & van der Giessen, 2015). No intervention is 
applied in the food chain. Opsteegh et al. (2015) Opsteegh described 
that cat vaccination, freezing of meat destined for raw or under-
cooked consumption and enhancing biosecurity in pig husbandries 
are potential interventions to further prevent T. gondii infections. 
Implementation of these interventions would most likely reduce the 
number of infections, but increase costs in several domains of soci-
ety at the same time. Toxoplasma infections in animals are generally 
asymptomatic, preventing infections in animals which result mostly in 
additional costs. However, there are some additional benefits for the 
farmers/food chain, such as a reduction in abortions in ewes when im-
plementing the cat vaccination intervention and less spilled feed due 
to rodent control when increasing biosecurity at pig farms. Freezing 
high- risk meat products has economic consequences for both the 
meat processing industry and consumers of the high- risk meat prod-
ucts. There may be a disbalance between stakeholder groups that have 
to pay for these interventions and stakeholder groups that will benefit 
from such interventions.
A social cost- benefit analysis (SCBA) is an established method to 
map the distribution of the short- term and longer- term costs and ben-
efits of implementing new interventions over the different stakehold-
ers involved in these interventions. Performing an SCBA implies the 
identification and valuation of all costs and all benefits of a certain 
intervention in monetary terms. The valuation of the costs and ben-
efits in an SCBA allows comparison and ranking of the results of the 
various interventions (Romijn & Renes, 2013). Within an SCBA, the 
overall sum of benefits and costs is reported as net social costs or net 
social benefit. This is the sum of all the valued benefits minus the sum 
of all the valued costs. If the monetized balance of the total costs and 
total benefits is positive, then this will lend support to implementa-
tion of these preventive interventions at the societal level. By allowing 
a ranking of these net social benefits of different interventions, the 
SCBA will help to decide which intervention is most worthwhile to be 
implemented.
Impacts
• Toxoplasma gondii infections cause a large disease burden 
in the Netherlands, with an estimated health loss of 1,900 
Disability Adjusted Life Years and a cost-of-illness esti-
mated at €44 million annually.
• Three possible preventive interventions: cat vaccination, 
freezing meat destined for undercooked consumption 
and enhancing biosecurity in pig husbandries bear costs 
for stakeholders in society that differ from those profiting 
from benefits.
• In a social cost-benefit analysis (SCBA), all costs and ben-
efits are identified, making explicit which stakeholder 
pays and who benefits. The results of the SCBA will guide 
policy making. If the balance of costs and benefits is posi-
tive, it will lend support to implementation of these pre-
ventive interventions.
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SCBAs are rarely performed when evaluating interventions 
affecting both human and animal health. Most evaluations focus 
either on the stable to slaughterhouse (animal health), or on public 
health domains and ignoring the other sectors. There are a few ex-
ceptions; some economic evaluations of zoonosis included a range 
of social costs and effects. For example, Sundstrom, Wahlstrom, 
Ivarsson, and Sternberg Lewerin (2014) assessed the net benefits 
of introducing alternative Salmonella control strategies taking ex-
pected changes in human and cattle morbidity and the associated 
monetary effects into account. Quality of life loss due to salmo-
nellosis could not be incorporated into the model. Babo Martins, 
Rushton, and Stark (2016, 2017) evaluated the economic effects 
of zoonosis surveillance. In the case of Campylobacter, costs of an 
animal and human monitoring system were included. In another 
economic evaluation, the social costs and effects of combined ra-
bies control interventions such as dog vaccination, and pre- and 
post- exposure prophylaxis in humans were assessed (Hasler et al., 
2014). Unlike our study, in the latter two studies, the benefits were 
not monetarized in Euros but only expressed in human infections 
and DALYs averted. Within health care, most economic evaluations 
concern cost- effectiveness analyses (CEAs). In a cost- effectiveness 
study, a scenario with a new intervention is often compared to a 
scenario without this intervention (mostly the current situation), 
and sometimes several interventions are compared among each 
other. In a CEA, the incremental cost- effectiveness ratio (ICER) 
shows the net costs of health improvement, for example in terms 
of costs per Life Year Gained (LYG) or DALY averted of the new 
intervention, compared to care as usual or to not implementing 
that intervention. Although most guidelines for economic evalu-
ation advocate the use of a societal perspective, in reality many 
analyses use a health care perspective (Belli, Anderson, Barnum, 
Dixon, & Tan, 1998, ZIN, 2015). In case a societal perspective is 
taken, this often is limited to the inclusion of productivity losses 
and additional patient costs, such as travel costs. Wider societal 
costs, such as those for the food production industry, are not taken 
into account in general. In addition, CEAs pay little attention to 
distributional aspects, regarding the stakeholders who pay for an 
intervention and who get the benefits. In contrast to CEAs, health 
benefits in SCBAs are expressed in a monetary unit (e.g. dollars 
or Euros), and not in a specific health outcome, such as DALYs or 
infections averted (Koopmans et al., 2016a,b; Romijn & Renes, 
2013; Treasury, 2015). The SCBA requires availability of data from 
all relevant domains. A well- performed SCBA is attractive because 
it takes into account both the inter- sectoral costs and benefits as 
well the distributional issues since the interventions impact several 
domains of society.
The aim of this article is to present the design of an SCBA in-
vestigating the costs and (monetarized) benefits of three preventive 
interventions with the objective to reduce the disease burden of 
toxoplasmosis in the Netherlands: (i) cat vaccination, (ii) freezing of 
high- risk meat products from cattle, pigs and sheep, (iii) enhancing bi-
osecurity on pig farms. Since SCBA is rarely applied in the field of zoo-
noses research, the design of such an approach might be of interest for 
all working in the One Health community.
2  | METHODOLOGY OF A SOCIAL COST 
BENEFIT ANALYSIS
For Dutch government decisions that involve several domains of so-
ciety, SCBA is the recommended analytical technique. The study will 
be performed according to the Dutch general guidelines for SCBAs 
F IGURE  1 Research steps of a Social 
Cost- Benefit Analysis (adapted from 
(Romijn & Renes, 2013))
Scoping the 
problem
What problems or opportunities will arise and how will they develop?
What policies will follw?
What solutions have potential?
Describe the most likely developments without policy
Impact = policy alternative – reference scenario
Describe the policies to be taken
Identify individual policies from packagas
Define multiple altrenatives and variants
Identify effects
Quantify effects
Value (in Euro’s) effects
Resources needed to implement the solution
Costs may be one-time or periodic, fixed or variable
Only the extra costs comared to the reference scenario
Identify key uncertainties and risks
Analyse the impact on outcomes
Relevant, accessible and clear
Accountability: transparency and reproducibility
Interpretation: What does the decision maker learns from the CBA?
Identify all the effects, also the non-qualified and / or non-valued
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and will follow steps recommended in these guidelines (see Figure 1) 
(Romijn & Renes, 2013; Koopmans et al., 2016b,a).
As shown in Figure 1, the guideline prescribes 8 steps that will be 
explained below.
2.1 | Step 1 scoping the problem
In this first step, the initial situation with regard to the problem at 
hand is determined. What is the size of the problem? What is the 
prevalence and incidence of toxoplasmosis, both in the animal and 
the human population, what are the consequences of toxoplasmosis 
in terms of disease burden in humans, and what are the consequences 
of toxoplasmosis in animals, if any, and what will be the trend into 
the future under the current interventions? Will the problem diminish, 
increase or stabilize and what are the main drivers for these future 
trends? The main aim of this step is to portray the current state of 
affairs (including the main actors) for toxoplasmosis in the Dutch so-
ciety. This step also includes an inventory of current interventions to 
prevent toxoplasmosis.
2.2 | Step 2 the reference scenario
In this step, the reference scenario will be described in terms of 
costs and consequences of continuing current interventions (un-
changed policies). Essentially, this is limited to creating awareness 
among pregnant women and advising on preventive measures that 
pregnant women can take themselves. No other interventions 
are currently in place, neither in the public health domain, nor at 
the farm or in the food chain. At the start of the project, all rel-
evant stakeholders are identified based on information from web-
sites, grey and scientific literature and on interviews with experts 
in the field and from scientific institutes (EFSA, 2011a,b, Kotula 
et al., 1991; Opsteegh, Kortbeek, & Giessen, 2011; Torgerson 
& Macpherson, 2011; Verma & Khanna, 2013) (Table 1). Human 
health care, agriculture in particular livestock holders, veterinarians, 
animal feed companies, food processing industry and education are 
involved with the interventions under study. The stakeholders will 
experience a change in costs and benefits due to the interventions. 
Furthermore, higher or lower prices will influence the producer and 
consumer surplus. A crucial assumption is that we assume that in-
terventions will be supported and adopted by all European coun-
tries. Therefore, we do not take into account import of non- frozen 
meat from abroad, nor the jeopardy for competitiveness should only 
one European country require food industry to freeze certain types 
of meat. Ultimately, the net benefits per stakeholder are presented. 
Defining the reference scenario is crucial, because this will be the 
scenario to which the costs and benefits of new interventions will 
be compared.
2.3 | Step 3 define the interventions
People can become infected via three main ways of transmission: 
ingesting uncooked meat containing tissue cysts, ingesting food 
and water contaminated with oocysts from infected cat faeces, 
and congenitally (Opsteegh et al., 2015). Since an effective human 
vaccine is lacking, prevention of zoonotic transmission from ani-
mals or environment to humans is therefore the most optimal al-
ternative. Cats are the main reservoir. Food animals can become 
infected via the environment or by ingesting water contaminated 
with oocysts from infected cat faeces. Reducing exposure to oo-
cysts or tissue cysts in humans can be achieved through (i) cat vac-
cination (ii) freezing of high- risk meat products and (iii) enhancing 
biosecurity on pig farms. The different domains and their effects 
for the different interventions are shown in Table 1 and described 
below.
2.3.1 | Ad 1
Vaccination of cats may be an effective way to reduce oocyst shed-
ding by cats in the environment (Opsteegh et al., 2015). The inter-
vention will directly influence human infections via oocysts in the 
environment but also infections via meat as it will reduce the preva-
lence of infection in livestock. The effects of cat vaccination in animals 
and humans will be modelled based on available literature or expert 
opinion.
Unfortunately, no vaccine is commercially available at this moment. 
However, in a vaccination- challenge experiment, use of a prospec-
tive vaccine prevented oocyst shedding in 31 of 37 kittens (Frenkel, 
Pfefferkorn, Smith, & Fishback, 1991). Depending on the proportion 
of cats that is domestic and the proportion that is not bound to a cer-
tain owner, it may be difficult to reach sufficient vaccination coverage. 
In this study, we consider both vaccinations of all owned cats or of 
cats that are kept at livestock farms only. Vaccination of cats can lead 
to fewer toxoplasma- related abortions in ewes. Most of all, there will 
be fewer human infections and consequently fewer cost- of- illness and 
disease burden.
2.3.2 | Ad 2
Freezing	 meat	 at	 −20°C	 for	 2	days	 will	 render	 tissue	 cysts	 non-	
viable (Kotula et al., 1991). Freezing (and thawing) of meat will 
have effects on the physical quality of meat. The formation of ice 
crystals during freezing damages the structure in the meat and 
leads to changes in the biochemical reactions that occur at the cel-
lular level of the meat (Lagerstedt, Enfalt, Johansson, & Lundstrom, 
2008; Leygonie, Britz, & Hoffman, 2012). Among other effects, it 
will lead to changes in moisture loss, colour, and pH, shear force 
and microbial spoilage (Utrera, Parra, & Estevez, 2014). In general, 
frozen meat is less juicy and tender, influencing consumers’ atti-
tudes towards freezing of meat negatively. Consequently, the price 
consumers are willing to pay for such products may be affected. 
Freezing meat will extend the meat production chain and therefore 
increases the risk of cross- contamination with other pathogens 
such as Salmonella spp. This may happen at the consumer level, but 
also during the freezing process or via staff at the freezing com-
pany. Due to data limitations, the aspect of cross- contamination 
     |  189SUIJKERBUIJK Et al.
will not be taken into account. Several mechanisms are available 
to mitigate the effects of freezing and thawing including the use of 
novel methods of freezing and thawing and modified atmospheric 
packaging (Leygonie et al., 2012). To reduce costs and increase ac-
ceptance of consumers, the freezing meat intervention will only 
be targeted at high- risk meat products. This will include meat pro-
ducts from animal species with a high prevalence of T. gondii such 
as sheep, and products that are commonly consumed raw or under-
cooked, such as steak, raw meat- slices and raw meat spreads. To 
identify the most relevant high- risk meat products, the quantitative 
microbial risk assessment (QMRA) model developed to attribute 
predicted T. gondii infections to specific meat products will be up-
dated for this SCBA, based on data from the new Dutch National 
Food Consumption Survey (Opsteegh, Prickaerts, Frankena, & 
Evers, 2011; Van Rossum et al., 2016). More information on this 
QMRA model is given in the model section below. Freezing will not 
affect the farm practice, and we therefore assume no impact of this 
intervention on food animal production. We only consider effects 
on human health.
2.3.3 | Ad 3
Controlled indoor husbandry (housing) has drastically reduced the 
prevalence of T. gondii infection in pigs and is considered an impor-
tant factor in the decrease in seroprevalence observed in human 
populations (Opsteegh et al., 2015). As in most European coun-
tries, a quality system is established in the Netherlands for the solid 
production of pork. Independent organizations monitor and assess 
working procedures and conditions of animal welfare, quality and 
food safety on pig farms. Everyone in the production chain, from 
farmer to butcher, can participate in this scheme. An European 
Food Safety Authority (EFSA) working group has suggested the fol-
lowing controlled housing conditions to prevent Toxoplasma infec-
tion in pigs (EFSA, 2011b):
TABLE  1 Domains in the society related to the three interventions







Consumer Toxoplasma- related patient costs will be assessed X X X
Consumer surplusa X
Consumption of meat may change due to change in meat price X
Costs for cat vaccination X
Human health Health care costs X X X
Morbidity and premature mortality due to toxoplasmosis are expressed in 
DALYs. All short- and long- term effects of infection will be included
X X X
Producers Producer surplusb. Since we consider freezing meat as an international 
intervention, the consequences for the producer surplus will be limited 
as additional costs might spill- through to the consumer.
X X
Biosecurity measures will lead to additional costs for pig farmers. X
Serological testing in slaughterhouses are additional costs for slaughter-
house that might be put through to the consumer, since we assume that 
this is an international intervention
X
Toxoplasmosis is an important cause of abortion among sheep. 
Vaccination of cats at farms can reduce these losses.
X
Facilities at companies will be needed such as freezers, extra surface area 
and electricity costs. These facilities will have additional annual recurrent 
costs (e.g. electricity, maintenance) leading to higher productivity costs 
for slaughterhouses and the meat processing industry.
X
Employees Toxoplasma- related productivity losses will be assessed X X X
Freezing of meat will lead to extra employment. X
The development, campaign, distribution and vaccination of cats will lead 
to extra employment for veterinarians
X
The biosecurity measures will affect employment of pig breeders, and 





A change in employment rate will affect social security and pensions. X X X
Education Less infections will lead to less special education X X X
aConsumer surplus is an economic measure of consumer benefit, which is calculated by analysing the difference between what consumers are willing and 
able to pay for a good or service relative to its market price, or what they actually do spend on the good or service. A consumer surplus occurs when the 
consumer is willing to pay more for a given product than the current market price.
bProducer surplus is an economic measure of the difference between the amount that a producer of a good receives (the market price) and the minimum 
amount that he or she would be willing to accept for the good. The difference, or surplus amount, is the benefit that the producer receives for selling the 
good in the market.
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1. keeping the animals indoors
2. keeping cats away from stables, feed, and bedding production and 
storage, more specifically avoid contact of (faeces of) cats with the 
feed
3. avoiding dead birds and rodents in the feed
4. implementing strict vermin control
5. availability of suitable clean clothing, shoes and protective equip-
ment for employees and visitors; use of separate boots, wheelbar-
row and other equipment to avoid bringing soil into the stables
6. providing clean drinking water and blocking access to surface water
These conditions are already partly included in the Dutch 
 quality system (integrated quality control) for pig farms. 
Serological monitoring can be a tool in detecting farms infected 
with T. gondii (Swanenburg, Boender, Heres, Koeijer, & Wisselink, 
2015). Preliminary results of collected sera showed an average of 
2% serological prevalence in pigs. Pigs from organic farms had a 
prevalence of 3.6% (Swanenburg et al., 2015). Also in Italy, anti- 
Toxoplasma antibodies were detected in 2.1% of pig carcasses 
from intensively reared pigs suggesting for additional on- farm 
preventive measures (Papini et al., 2017). It seems that at high- 
risk farms having seropositive pigs, rodent control is less well 
performed and many of these farms have outside bulk storage of 
some feed constituents, which may be accessible for rodents and/
or cats (Heres et al., 2015). In this SCBA, we assume serological 
monitoring of pigs at moment of slaughter; seropositive results 
will lead to an audit and tailor made advice for farmers with for 
example the imposition of additional rodent control, etc. Stricter 
biosecurity measures might result in a lower prevalence in pigs, 
and consequently fewer human infections. A side effect of the bet-
ter biosecurity measures might be that rodents spoil fewer feed, 
resulting in lower feed costs.
2.4 | Step 4 define and value benefits
Following step 3 where the effects and impacts of the new policies 
were defined, monetary values (in Euro) have to be assigned to the 
benefits of the interventions for the Netherlands. Three models are 
used to assess these effects with respect to number of infections, 
transmission of T. gondii, and burden of disease (see section 3). Using 
Havelaar’s model, and recent European disability weights, health gains 
of avoided infections in terms of DALYs averted will be estimated 
(Haagsma et al., 2015; Havelaar et al., 2012) and valued in monetary 
terms. Based on the same outcome tree Mangen et al. (2015, 2017) 
estimated the health care costs, patients’ costs and costs in other sec-
tors (i.e. productivity losses and special education). We will use up-
dated estimates for the year 2016 when estimating savings in health 
care costs, patients’ cost as well as gain in productivity and savings 
regarding special education due to less complications of toxoplas-
mosis. The monetary value of an averted DALY will be taken from 
Dutch recommendations for SCBA in the social domain in which the 
value of a Quality Adjusted Life Year is described. We assume that 
the monetary value of a DALY corresponds with the monetary value 
of the QALY ranging between 50.000 and 100.000 Euro (Koopmans 
et al., 2016a). The benefits will mostly affect consumers since they 
experience less Toxoplasma- related infections, productivity losses and 
special education.
2.5 | Step 5 define and value costs
The aim of this step will be to use state- of- the- art valuation methods 
for carefully costing all resource use involved in the different interven-
tions for the Netherlands. Various approaches will be needed, either 
using reference values for health care costs (Zorginstituut_Nederland, 
2015) or for non- health outcomes (Drost, Paulus, Ruwaard, & Evers, 
2013; Koopmans et al., 2016a), or using a relevant valuation method 
(hedonic pricing or contingent valuation). Intervention costs will be 
estimated based on literature and via field experts. The price for 
 freezing meat is based on market prices; however, consumers’ pref-
erences on frozen meat are unknown. Therefore, we will perform a 
Discrete Choice Experiment (DCE), a type of contingent valuation in 
which preferences of consumers can be assessed. The so- called at-
tributes, items that are important for consumers’ decisions, will be 
taken from the literature and interviews with experts. Using a price 
proxy, we come close to estimation for the willingness to pay for fro-
zen meat (hence, the willingness to pay for avoidance of infection risk) 
or the amount of compensation consumers may want for frozen meat 
(hence, the compensation needed to forego consumption of fresh 
meat). We can use this estimate to determine the consumers’ surplus, 
the monetary value of the benefit that they accrue from consuming 
types of meat important in the transmission of toxoplasmosis. The 
costs will initially affect the pig farmers who pay for the enhanced 
biosecurity, the cat owners who pay for the vaccination (who are 
in practice also consumers) and the freezing companies for freezing 
meat. Serological costs will be paid by the slaughterhouse who, we 
might assume transfer these costs to the consumer. The same applies 
for the freezing costs which are spilled- over to the consumer, result-
ing in slightly higher consumer prices.
2.6 | Step 6 assess the net present value
This step considers the summation of the monetized costs and ben-
efits using an Excel model (see section 3) to obtain a net present value 
in Euros per intervention measure. It also includes presenting a list of 
different stakeholders involved and provides detailed insight into the 
gains and losses for the different stakeholders over time.
2.7 | Step 7 conduct sensitivity analyses
Uncertainty is interpreted in a broader sense than merely statistical 
uncertainty (as represented by 95% intervals). This assessment in-
volves the identification and characterization of all uncertainties of 
the models using an uncertainty typology (Knol, Petersen, van der 
Sluijs, & Lebret, 2009). Such a typology helps to characterize uncer-
tainty sources with respect to the place where the source of uncer-
tainties manifested (e.g. study boundaries or in the model structure), 
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the nature of the uncertainty (lack of knowledge or variability) and its 
range (probabilistic or scenario- based).
2.8 | Step 8 present outcomes
Here we present a conclusion of the economic consequences for so-
ciety with respect to the interventions under study. We report the 
outcomes of both the main analysis and the sensitivity analyses in 
agreement with the pertinent guideline for reporting economic evalu-
ations in a transparent and replicable way (Husereau et al., 2013). This 
will be done for each of the interventions under review and include 
a list of the non- monetized costs and benefits and will be comple-
mented by a research agenda to address the most salient knowledge 
gaps identified by our study.
Because costs (investments) have to be made now and effects 
will spread out over many years, it is common in an SCBA to use a 
time horizon that covers as many costs and effects as possible. A dis-
count rate is used because costs and benefits in the future are valued 
less than in the present. The time horizon used in our model will be 
10 years, and the discount rate of 3% is conform the advice of the 
Dutch Ministry of Finance (van Ewijk et al., 2015).
3  | THE MODELS
Four different models will be employed to estimate the societal costs 
and benefits of three different interventions:
3.1 | The QMRA model: relative attribution of 
meatborne infections in humans
The QMRA makes it possible to quantify the contribution of sheep, 
pork and beef products to predicted T. gondii infections in the Dutch 
population (Opsteegh et al., 2015). The model takes the following 
steps: (i) calculating the number of bradyzoites per infected portion, 
(ii) estimating the reduction by salting, followed by freezing and fi-
nally heating, (iii) estimating the probability of human infection per 
infected portion using a dose–response relation, (iv) multiplying the 
outcome of c with the prevalence of T. gondii per livestock species to 
estimate the probability of infection per portion and (v). multiplying 
the probability of infection per portion with the consumed number of 
portions per year to predict the total number of infections per meat 
product. The previously published model, which uses consumption 
data from 1997 and 1998, will be updated with new data from the 
Dutch National Food Consumption Survey. The incidence of human 
infections without and with intervention (i.e. freezing, improved bi-
osecurity) will be the outcome of this model, and the estimated dif-
ference will be the input for the SCBA model. Improving biosecurity 
measures on pig farms is assumed to result in a lower prevalence in 
pigs, and consequently in pork. Since prevalence data on the expected 
effectiveness of improved biosecurity are still in process in a current 
project, we will assume that the effectiveness of this intervention will 
result in a lowered prevalence in pigs and anticipate that the lower 
prevalence in pigs results in a lower number of contaminated pork 
products. This will lead to a lower number of human toxoplasma cases 
in the QMRA model.
3.2 | The T. gondii transmission model in 
cats and their environment
In an epidemiological model, T. gondii transmission with respect 
to cat vaccination as described by Lelu, Langlais, Poulle, and Gilot- 
Fromont (2010)) will be modified. This is a so- called SIR- model, a dis-
ease compartment model existing of 3 compartments: S=susceptible, 
I=infectious and R=recovered. The cat population is split into these 
three compartments, and the prey population (mice) is divided into 
two compartments, susceptible and infected mice. Because cats are 
assumed to defecate in the area of their habitat, there is a limited 
surface that can be contaminated by oocysts. Therefore, the envi-
ronment exists of two compartments: uncontaminated and contami-
nated defecating areas. The model will consider different proportions 
of vaccinated cats, ranging from 0 to 1, to study to what extent these 
various vaccination levels would reduce the presence of oocysts in 
the environment. Encountering an infectious oocyst dose is assumed 
to follow a Poisson process. Therefore, due to the relatively small dis-
ease incidence rate, the risk of exposure to any oocyst dose becomes 
proportional to the number of oocyst present in the environment. By 
combining a dose–response relation with risk of exposure, we will 
calculate the expected number of oocyst- driven infections and how 
their number is reduced with the various vaccination levels. There is 
no clear human dose–response relation with regard to oocyst expo-
sure, but data from several animal studies suggest that the response 
is similar among mice, rats and pigs (Dubey, 1996, 2006; Dubey & 
Frenkel, 1973; Dubey, Speer, Shen, Kwok, & Blixt, 1997; Dubey et al., 
1996). We will construct a dose–response relation based on these 
data as we have no reason to assume that for humans it would be 
different.
3.3 | Disease burden model
The outcome of infection in terms of diseases caused by T. gondii is 
expressed in DALYs (Havelaar et al., 2012), in which a DALY is the 
sum of the number of years of life lost (YLL) due to diseases caused by 
T. gondii and the number of years lived with a disability (YLD) caused 
by T. gondii (DALY = YLL+YLD). YLL is calculated by summation of all 
fatal cases due to all health outcomes of T. gondii multiplied by the 
expected individual life span at the age of death. YLD is the sum of 
outcomes of all cases of which duration of the illness and the disability 
weights of a disease caused by T. gondii are multiplied.
We attribute toxoplasma disease incidence, disease burden and 
the cost- of- illness to different exposure pathways, based on an expert 
elicitation study (Havelaar, Galindo, Kurowicka, & Cooke, 2008). This 
study estimated the fraction of all human cases by five major pathways 
(i.e. food, environment, direct animal contact, human–human trans-
mission and travel). The foodborne pathway was further subdivided 
into 11 food groups (e.g. pork, sheep, cattle).
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3.4 | The SCBA model
The SCBA model is implemented as a Microsoft Excel model. The 
SCBA model synthesizes all available input from the above- mentioned 
models. Results are transformed into overall costs and benefits as-
sociated with the interventions considered in this project (Figure 2).
The model includes:
1. the costs of implementing (and enforcing) the three different 
interventions directed at diminishing exposure to T. gondii;
2. the effects of the interventions on the exposure to T. gondii;
3. the costs and benefits associated with reduced T. gondii exposure 
for the different domains as listed in Table 1.
There are several types of input data to the SCBA model
1. Pig farm data (number of farms, pigs, tested pigs at slaughter, 
amount of pig feed);
2. Cat population data (owned cats, stray cats and cats at farms);
3. Meat consumption data (annual number of portions of risk meat 
per person, total amount of consumed risk meat);
4. Cost data (costs with respect to cat vaccination, freezing meat, en-
hancing biosecurity pig farms as well as healthcare costs, productiv-
ity losses and special education costs)
5. Quality of life data (toxoplasma-related disease burden and prema-
ture deaths)
The Excel model determines the net costs and benefits of the 
three interventions by comparing the reference scenario (with no 
additional policies) with alternative scenarios including reduced 
Toxoplasma transmission by simply calculating the difference be-
tween the costs in the alternative and the reference scenario. Net 
results are presented per intervention: undiscounted per year, dis-
counted for the 10- year period and also per stakeholder: consumers, 
freezing meat companies, farmers, slaughterhouses and government.
4  | CONCLUSION
This SCBA will provide evidence on the effectiveness and net ben-
efits of promising interventions targeted at toxoplasmosis. In ad-
dition, this study will clarify potential barriers and facilitators of 
implementation. As toxoplasmosis has a high disease burden and 
prevention is currently limited to health education for specific risk 
groups, more effort to reduce transmission of T. gondii is warranted. 
As far as we know this study is the first that investigates the long- 
term social costs and benefits for society of toxoplasmosis- related 
preventive interventions. The SCBA will present which intervention 
leads to the greatest welfare gains and shows who has to pay for 
these welfare gains and who ultimately benefits most. Both aspects 
are of importance for policy measures. Since SCBAs in the field of 
public health are relatively scarce, the study will contribute to our 
understanding of the feasibility of SCBAs targeted at other zoon-
oses with high consequences for society. Other challenging issues 
during this project will be the unravelling of data targeted at avoid-
ance of double counting in the domains affected, as well as the 
management of impaired data in the several domains of society for 
valid calculations in the SCBA.
The research described herewith will present a full picture of socio- 
economic benefits of preventive strategies against a zoonosis with a 
high disease burden in order to give decision makers recommendations 
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